SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/320612"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/320612" > Short-acting β2 -ag...

Short-acting β2 -agonist use and asthma exacerbations in Swedish children: A SABINA Junior study.

Melén, Erik (författare)
Karolinska Institutet,Karolinska Institute,Sachs’ Children and Youth Hospital
Nwaru, Bright I, 1978 (författare)
University of Gothenburg,Gothenburg University,Göteborgs universitet,Krefting Research Centre
Wiklund, Fredrik (författare)
Statisticon
visa fler...
de Fine Licht, Sofie (författare)
AstraZeneca, Sweden
Telg, Gunilla (författare)
AstraZeneca, Sweden
Maslova, Ekaterina (författare)
AstraZeneca, UK
van der Valk, Ralf J P (författare)
AstraZeneca, UK
Tran, Trung N (författare)
AstraZeneca, UK
Ekström, Magnus (författare)
Lund University,Lunds universitet,Palliativt Utvecklingscentrum,Forskargrupper vid Lunds universitet,Andfåddhet och kronisk andningssvikt,The Institute for Palliative Care,Lund University Research Groups,Breathlessness and chronic respiratory failure
Janson, Christer (författare)
Uppsala University,Uppsala universitet,Lung- allergi- och sömnforskning
visa färre...
 (creator_code:org_t)
2022-11-21
2022
Engelska.
Ingår i: Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. - : Wiley. - 1399-3038 .- 0905-6157. ; 33:11
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • In adults and adolescents with asthma, use of ≥3 short-acting β2 -agonist (SABA) canisters/year is associated with increased exacerbation risk. Whether this association is present in younger children remains unknown. In this SABA use IN Asthma (SABINA) Junior study, we assessed the association of SABA collection with exacerbation risk in the general Swedish pediatric asthma population.This population-based cohort study utilized linked data from the Swedish national healthcare registries involving patients with asthma (<18years) treated in secondary care between 2006-2015. Exacerbation risk, by baseline SABA collection (0-2 vs. ≥3 canisters, further examined as ordinal/continuous variable) and stratified on comorbid atopic disease (allergic rhinitis, dermatitis and eczema, and food/other allergies), was assessed for 1-year follow-up using negative binomial regression.Of 219,561 patients assessed, 45.4%, 31.7%, and 26.5% of patients aged 0-5, 6-11, and 12-17years, respectively, collected ≥3 SABA canisters during the baseline year (high use). Collection of ≥3 SABA canisters (vs. 0-2) was associated with increased exacerbation risk during follow-up (incidence rate ratios [95% confidence interval]: 1.35 [1.29-1.42], 1.22 [1.15-1.29], and 1.26 [1.19-1.34] for 0-5-, 6-11-, and 12-17-year-olds, respectively); the association persisted with SABA as a continuous variable and was stronger among patients without atopic diseases (32%-44% increased risk versus. 14%-21% for those with atopic disease across groups).High SABA use was associated with increased asthma exacerbation risk in children, particularly in those without comorbid atopic diseases, emphasizing the need for asthma medication reviews and reformative initiatives by caregivers and healthcare providers on SABA use.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Hälsovetenskap -- Folkhälsovetenskap, global hälsa, socialmedicin och epidemiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Health Sciences -- Public Health, Global Health, Social Medicine and Epidemiology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Nyckelord

Adult
Adolescent
Humans
Child
Cohort Studies
Sweden
epidemiology
Asthma
drug therapy
epidemiology
Rhinitis
Allergic
SABINA junior study
asthma
children
exacerbations
pediatric
SABINA junior study
short-acting β-agonists

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy